16th week of 2020 patent applcation highlights part 8 |
Patent application number | Title | Published |
20200113815 | WATERY LOTION SKIN CARE COMPOSITIONS AND METHODS - A watery lotion composition for topical application to skin comprising at least one extract from the fermentation of the microorganism | 2020-04-16 |
20200113816 | REACTIONS TRIGGERED BY COOLING-INDUCED GEL-TO-SOL TRANSITION OF THERMORESPONSIVE POLYMERS - Provided are pharmaceutical compositions, which include a gel comprising a thermoresponsive polymer, the polymer being soluble in water at a temperature of 37° C. or lower; and a therapeutic compound, or a pharmaceutically acceptable salt thereof, dispersed in the gel. Also provided are methods of delivering a therapeutic compound, which include administering the disclosed pharmaceutical composition to a subject in need thereof (e.g., by subcutaneous administration). | 2020-04-16 |
20200113817 | INTRAVESICAL DRUG DELIVERY DEVICE WITH RETENTION FRAME AND DRUG TABLETS - Intravesical drug delivery devices that include a device body, a number of solid drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The drug tablets is positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen. | 2020-04-16 |
20200113818 | DENTAL STRIPS FOR THE DELIVERY OF SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDES - In certain embodiments a dental strip for the prevention or reduction of dental caries is provided. In certain embodiments the dental strip is constructed to deliver effective amounts of specifically targeted antimicrobial peptides (or simple antimicrobial peptides) and comprises an orally compatible backing layer, a delivery layer disposed on one surface of the backing layer where the delivery layer comprises an orally compatible polymer, or combination of polymers, and a specifically targeted antimicrobial peptide (and/or simple antimicrobial peptide) capable of binding and killing | 2020-04-16 |
20200113819 | Composition for Transdermal Delivery of Cationic Active Agents - The invention relates to a composition for transdermal delivery, particularly iontophoretic transdermal delivery, of at least one cationic active agent or a salt thereof. The composition includes at least one cationic active agent or a salt thereof, at least one polyamine or/and polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. The invention further relates to the use of such composition as a component of a transdermal patch or of an iontophoretic transdermal patch, as well as to the use of such composition in a method for transdermally and/or iontophoretically administering cationic active agents. The invention further includes methods for determining the in vitro skin permeation properties of an active-agent-containing iontophoretic composition. | 2020-04-16 |
20200113820 | INTRATUMOUR INJECTION FORMULATION - Formulations and uses of the formulations for treating a malignant mass in a mammal by administering an injectable formulation comprising a therapeutically effective amount of a chemotherapeutic agent dissolved or suspended in a biocompatible carrier directly into the malignant mass are disclosed. In certain preferred embodiments, the injectable formulation is a taxane (e.g. paclitaxel), a podophyllotoxin derivative (e.g., etoposide), or a camptothecin derivative (e.g., hydroxycamptothecin). | 2020-04-16 |
20200113821 | COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY - Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Growth factors can be delivered to correct structural defects. Gene editing can be carried out utilizing a gene editing composition such as triplex-forming molecules, CRISPR, zinc finger nucleases, TALENS, or others. The methods can include administration of a gene modification potentiating agent such as stem cell factor (SCF), a CHK1 or ATR inhibitor, or a combination thereof. A particularly preferred gene editing composition is triplex-forming peptide nucleic acids (PNAs) substituted at the γ position for increased DNA binding affinity. Polymeric particle compositions for extracellular and intracellular delivery of the active agents are also provided. | 2020-04-16 |
20200113822 | COMPOSITION AND METHOD FOR REDUCING ALLERGIC RESPONSE - A method and kit for the sequential early introduction to an infant of at least two allergens to decrease the infant's risk for developing allergies, the method involving administering an initial lower, exposure dose of a first allergen for a day or two, followed by administering a higher maintenance dose of the first allergen for several days, followed by administering the maintenance dose of the first allergen and an initial lower, exposure dose of a second allergen for a day or two, followed by administering the higher maintenance dose of the first allergen and a higher maintenance does of the second allergen for several days. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula or to mother's milk. Alternatively, the allergens can already be provided in baby formula, or in other foods such as snack bars, cookies, or gels. | 2020-04-16 |
20200113823 | TABLETS WITH IMPROVED ACCEPTANCE AND GOOD STORAGE STABILITY - The present invention relates to tablets for animals, having improved acceptance and good storage stability. | 2020-04-16 |
20200113824 | DISPENSING CAP CONTAINING A SOLUBILISATE OF A PHARMACEUTICALLY ACTIVE AGENT OR DIETARY SUPPLEMENT - The present invention relates to a dispensing cap for the delivery of a fluid solubilisate, a beverage system configured for the use of such a dispensing cap and a method for preparing a beverage by means of such a beverage system. Poorly water-soluble dietary supplements or pharmaceutical active agents can be delivered in this new dosage form in order to increase the bioavailability of these substances. The solubilisate has been solubilized without a polysorbate. | 2020-04-16 |
20200113825 | Tea Composition For Oral Administration - This invention concerns an enhanced green tea based product for oral use whereby the nutritional and health benefits of green tea, and additives which shall include some combination of flavoring, preservatives, caffeine, humectants, and water, can be ingested and absorbed by the user. | 2020-04-16 |
20200113826 | SUSPENSION COMPRISING ALUMINUM HYDROXIDE AND MAGNESIUM HYDROXIDE AND PREPARATION METHOD THEREFOR - The present invention provides a suspension comprising aluminum hydroxide and magnesium hydroxide and a method of preparing the same. The aqueous suspension composition according to the present invention ensures an excellent sedimentation rate by using a mixed suspending agent with a specific composition, so that insoluble aluminum hydroxide and magnesium hydroxide do not easily settle, do not form a cake, and are easily redispersed. Since the aqueous suspension composition having an excellent sedimentation rate has not only physical stability, but also forms a homogeneous dispersion system, the reproducibility or effectiveness of bioavailability may be ensured. In addition, the aqueous suspension composition according to the present invention provides an excellent texture, and thus patient compliance increases. | 2020-04-16 |
20200113827 | EMULSIFIED FATTY ACIDS - Provided herein are methods and processes for emulsifying non-polar compounds, such as omega fatty acids. Also provided are compositions that can be prepared according to the methods and processes described herein. The compositions, for example, have a high amount of the non-polar compound, such as a large amount of omega fatty acids. The non-polar compounds are also present in very small droplets within composition. For example, the mean or median particle size of the droplets is less than about 5 μm. Further, the composition includes a low amount of surfactant, such as less than about 10-15% of the surfactant. | 2020-04-16 |
20200113828 | Thermally Stabilized Nanoemulsion - This invention describes of a means of stabilizing lipophilic drugs for long-term storage by incorporating them into a “thermally stabilized nanoemulsion” that has a phase transition temperature that is at or below the body temperature of 37 C and above a storage temperature of 4-8 C. One or more lipid soluble drugs are incorporated into the nanoemulsion at an elevated temperature above the phase transition temperature of the nanoemulsion and then stabilized for extended storage by lowering the temperature to below its phase transition temperature. This causes the nanoemulsion to transform into solid lipid nanospheres entrapping the drug within the solid lipid matrix. Upon rewarming the lipid nanospheres they will reconvert to an oil-in-water nanoemulsion suitable for administration to the patient in need. This invention further discloses disease targeting thermally stabilized nanoemulsions utilizing targeting agents such as antibodies, aptamers, binding peptides, hormones, cytokines and the like, attached to the exterior of the nanodroplets comprising the nanoemulsion. | 2020-04-16 |
20200113829 | METHODS FOR REDUCING SIDE EFFECTS OF IMMUNOTHERAPY - This invention provides methods to overcome the current limitations of immune checkpoint immunotherapy to provide more effective methods of treating cancer. In embodiments this invention provides a means of using of p53 gene therapy to augment immune checkpoint inhibition by combining antibodies targeting immune checkpoint molecules with SGT-53, a nanomedicine carrying a plasmid encoding human wild-type p53. This invention provides means of increasing tumor immunogenicity, enhancing both innate and adaptive immune responses, and reducing tumor-induced immunosuppression, sensitizing otherwise refractory tumors to anti-immune checkpoint antibodies. In other embodiments this invention also unexpectedly reduces immune-related toxicities that are seen with immunotherapies. | 2020-04-16 |
20200113830 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA - Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases, | 2020-04-16 |
20200113831 | LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES - Nucleic acid immunisation is achieved by delivering a RNA encapsulated within a liposome comprising a cationic lipid, wherein the liposome and the RNA have a N:P ratio of between 1:1 and 20:1. | 2020-04-16 |
20200113832 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY - The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP. | 2020-04-16 |
20200113833 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF - The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition. | 2020-04-16 |
20200113834 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF - The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition. | 2020-04-16 |
20200113835 | INJECTABLE LONG-ACTING NALTREXONE MICROPARTICLE COMPOSITIONS - The present disclosure relates to naltrexone sustained release microparticle delivery systems for the treatment of diseases ameliorated by naltrexone. The injectable microparticle delivery system includes naltrexone encapsulated in biodegradable microparticles administered in a pharmaceutically acceptable vehicle. | 2020-04-16 |
20200113836 | METHOD OF PREPARING SUSTAINED-RELEASE DRUG MICROPARTICLES WITH EASY RELEASE CONTROL - The present invention relates to a method of preparing sustained-release drug microparticles allowing easy release control. According to the method of the present invention, as can be seen in Examples of the present invention, an initial release amount may be easily controlled by simply adjusting the evaporation temperature of a solvent in a conventional method of preparing microparticles. In addition, since no additional process is required, a drug loading rate may be significantly increased, and since high temperature is not required, the stability of a drug that is weak to heat may be ensured. | 2020-04-16 |
20200113837 | IN SITU CELL DELIVERY USING RECONSTITUTED PHOTOPOLYMERIZED CHONDROITIN SULFATE GLYCOSAMINOGLYCAN HYDROGEL MATRICES - Disclosed herein are compositions and methods for cellular reconstitution of photopolymerized, lyophilized, bioactive chondroitin sulfate glycosaminoglycan (CS-GAG)-based hydrogel matrices. | 2020-04-16 |
20200113838 | COMBINATION AND USES AND TREATMENTS THEREOF - Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof. | 2020-04-16 |
20200113839 | Extended Release Highly Loaded Drug Compositions - The disclosed technology provides improved drug compositions that provide increased stability, higher drug loading potential, and suitable drug dissolution properties, and methods of making the same. The composition include: (a) a drug component comprising a therapeutically effective amount of a drug; (b) an extended release component comprising a cross-linked polyacrylic acid polymer that is a carbomer homopolymer, carbomer copolymer, carbomer interpolymer, polycarbophil or a mixture thereof; and (c) a buffering component comprising a magnesium containing buffering agent; wherein the drug component makes up at least 50% by weight of the composition. | 2020-04-16 |
20200113840 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES - Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form. | 2020-04-16 |
20200113841 | Extended Relief Dosage Form - A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours. | 2020-04-16 |
20200113842 | TABLET - The tablet of the present invention is a tablet | 2020-04-16 |
20200113843 | EYE-INJECTABLE POLYMERIC NANOPARTICLES AND METHOD OF USE THEREFOR - The present invention refers to a method for treating visual deficits comprising at least one step of injecting in the eye of a subject in need thereof a therapeutically effective amount of photoactive nanoparticles (NPs) or a composition comprising said photoactive nanoparticles (NPs). | 2020-04-16 |
20200113844 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF - The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide). | 2020-04-16 |
20200113845 | Abuse and Misuse Deterrent Transdermal Systems - An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants. | 2020-04-16 |
20200113846 | A TOPICAL OCULAR SUSPENSION OF ANTIOXIDANTS - A topical ocular suspension for treating or preventing age related macular degeneration (ARMD) comprising of one or more antioxidants and at least one pharmaceutically acceptable excipient, wherein the antioxidant is a carotenoid selected from lutein, zeaxanthin or a combination thereof. | 2020-04-16 |
20200113847 | METHODS AND FORMULATIONS FOR TREATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - The invention provides a formulation of cannabidiol and delta-9-tetrahydrocannabinol. The formulation is a solid oral dosage form. In some embodiments, the formulation is an oral liposomal formulation. The present invention also provides methods of treating chemotherapy-induced nausea and vomiting by administering such formulations to a patient before and/or after the patient receives chemotherapy treatment. The chemotherapy-induced nausea and vomiting being treated can comprise acute chemotherapy-induced nausea and vomiting, delayed chemotherapy-induced nausea and vomiting, or both. | 2020-04-16 |
20200113848 | COMPOSITIONS FOR AMELIORATING, PREVENTING OR TREATING SOMNIPATHY INCLUDING PHLOROGLUCINOL AS ACTIVE INGREDIENT AND COMPOSITIONS FOR SUPPRESSING TOLERANCE TO OR ALLEVIATING SIDE EFFECTS OF AGONIST AT BENZODIAZEPINE BINDING SITE OF GABA-A RECEPTOR INCLUDING PHLOROGLUCINOL AS ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol as an active ingredient and a health functional food composition for ameliorating somnipathy including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, do not cause tolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration, and do not cause side effects of a conventional agonist at the benzodiazepine binding site of the GABA-A receptor. The present invention also relates to a pharmaceutical composition for suppressing tolerance to or alleviating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient and a health functional food composition for suppressing tolerance to or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention can alleviate side effects of the agonist or can suppress tolerance to the agonist resulting from long-term administration. The present invention also relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol and an agonist at the benzodiazepine binding site of the GABA-A receptor as active ingredients. The pharmaceutical composition of the present invention uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to alleviate side effects of the agonist or suppress tolerance to the agonist resulting from long-term administration. | 2020-04-16 |
20200113849 | ALCOHOL-BASED COMPOSITIONS AND USES THEREOF - This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit. | 2020-04-16 |
20200113850 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION - Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus. | 2020-04-16 |
20200113851 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF - The invention provides oral liquid midodrine formulation and uses thereof. | 2020-04-16 |
20200113852 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS - Disclosed herein are methods and compounds for treating a cancer is characterized with an elevated expression of thioredoxin reductase (TrxR) or an elevated expression of peroxiredoxin (PRDX). In some embodiments, also disclosed herein are methods of selecting subjects for treatment or monitoring the treatment progress based on a biomarker panel. | 2020-04-16 |
20200113853 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 2020-04-16 |
20200113854 | Composition for Improving Brain Function - A composition for improving brain function contains acetic acid and/or an acetic acid salt as an active ingredient. Further suitably, the brain function improvement is brain dysfunction improvement or cognitive dysfunction improvement. Further suitably, the cognitive dysfunction is Alzheimer's-type dementia or vascular dementia. Further suitably, the composition is for oral intake. Further suitably, the composition is a food or drink composition for improving brain function. | 2020-04-16 |
20200113855 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING LACTATE METAL SALT - The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer matastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention as disclosed inhibit the growth of cancer cells and induce the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibit the expression of factors inducing resistance against radiation exposure, while having no side effects. Therefore, the lactate metal salt can be widely utilized in a more effective anti-cancer therapy. | 2020-04-16 |
20200113856 | NON-PRESCRIPTION MOTION SICKNESS MEDICATION CONTAINING AN ANALGESIC, AN H2 BLOCKER, AND AT LEAST ONE ANTACID - The present invention provides a compounded non-prescription medication for the treatment of motion sickness. The medication comprises: at least one analgesic selected from the group consisting of acetaminophen, ibuprofen, naproxen and salicylates; at least one histamine H | 2020-04-16 |
20200113857 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY - Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent. | 2020-04-16 |
20200113858 | HUMAN DIETARY SUPPLEMENT AND METHOD FOR TREATING DIGESTIVE SYSTEM AND IMMUNE-RELATED DISORDERS - A dietary supplement and methods for the manufacture and administration of the same are disclosed for the treatment and/or prevention of digestive disorders and immune-related disorders. The dietary supplement of the present invention is orally administrable, and may be compounded either in a solid form (including bars, wafers or pills), a paste form, a granular form, a powder form, or a liquid form. The ingredients of the dietary supplement of the present invention when combined provide a synergistic efficacy which greatly exceeds the sum of the efficacies of the individual ingredients, making the dietary supplement highly effective in the treatment and/or prevention of digestive disorders and immune-related disorders. The dietary supplement of the present invention is compounded so as to increase the impermeability of the gut lining as well as to balance the bacteria components of the microbiota, thereby minimized systemic inflammation, the cause of most chronic diseases. | 2020-04-16 |
20200113859 | SUBSTANCES FOR TREATMENT OF FATTY LIVER-RELATED CONDITIONS - There is provided a composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate ribonucleoside, nicotinamide and/or nicotinate, wherein the molar ratio of A) to D) is between 250:1 and 1.5:1 and the molar ratio of A) to B) is between 16:1 and 1:4. The composition may be used in a method of treatment of a medical condition selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), type 2 diabetes, obesity, insulin resistance and dyslipidemia. | 2020-04-16 |
20200113860 | NUTRITIONAL SUPPLEMENT FOR IMPROVED CALCIUM ABSORPTION - An inventive nutritional supplement for increased Ca absorption is disclosed. The inventive nutritional supplement incorporates Ca in combination with specified amounts of L-Arginine and L-Lysine. The inventive nutritional supplement may also include Copper, Zinc, Manganese and Vitamin D3 as specified herein. | 2020-04-16 |
20200113861 | Compounds and Methods for Modulating Vascular Injury - Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that find use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions find use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g., restenosis), and applications related to chronic inflammatory diseases of the vascular | 2020-04-16 |
20200113862 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2020-04-16 |
20200113863 | Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases - The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor β-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention. | 2020-04-16 |
20200113864 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2020-04-16 |
20200113865 | METHOD OF TREATING PATIENTS WITH A FACTOR Xa INHIBITOR, ASPIRIN, AND VERAPAMIL - The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered aspirin and verapamil. | 2020-04-16 |
20200113866 | METHODS FOR TREATING OBESITY - The present invention relates to methods of treating overweight or obesity, reducing fat, sugar, and food intake, and reducing body weight or body weight gain in a subject using geranium oil or orlistat mouthwash, or a combination of both. | 2020-04-16 |
20200113867 | COMPOSITION FOR IMPROVEMENT OF SLEEP OR FOR PREVENTION OR TREATMENT OF SLEEP DISORDERS, CONTAINING BETA-LAPACHONE - The present invention relates to a pharmaceutical composition or a health functional food composition for improving sleep or preventing or treating sleep disorders comprising beta-lapachone as an active ingredient. Beta-lapachone decreases the sleep latency and increases the total sleeping time, and thus the composition comprising the beta-lapachone can effectively improve sleep and prevent and treat sleep disorders. | 2020-04-16 |
20200113868 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATION WITH BRAIN IRON ACCUMULATION - The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration in with brain iron accumulation (NBIA). Studying two novel genes, namely, CRAT encoding the carnitine acetyltransferase and REPS1 involved in endocytosis and vesicle transport, and a series of known NBIA genes, the inventors reported on iron overload related to increased levels and abnormal recycling of transferrin receptor as a common feature in NBIA. They ascribe this anomaly, at least in part, to impaired palmitoylation of the receptor as a common consequence of the various disease causing mutations. Finally, the inventors show that Artesunate improved TfR1 palmitoylation in NBIA fibroblasts. In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation. | 2020-04-16 |
20200113869 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 2020-04-16 |
20200113870 | TINOSTAMUSTINE FOR USE IN TREATING SARCOMA - There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof. | 2020-04-16 |
20200113871 | TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA - T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof. | 2020-04-16 |
20200113872 | Ifetroban Treatment for Systemic Sclerosis - The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof. | 2020-04-16 |
20200113873 | MEDICAMENT - To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). | 2020-04-16 |
20200113874 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE - Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions. | 2020-04-16 |
20200113875 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY - The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS). | 2020-04-16 |
20200113876 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE - Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor. | 2020-04-16 |
20200113877 | HSP90 TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF - Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases. | 2020-04-16 |
20200113878 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase - The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota β-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma. | 2020-04-16 |
20200113879 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE - A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B. | 2020-04-16 |
20200113880 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITION - The purpose of the present invention is to provide: a pharmaceutical composition that comprises the pyridylaminoacetic acid compound of the present invention, said pyridylaminoacetic acid compound being stable within the pharmaceutical composition; and a method for improving the stability of the pydridylaminoacetic acid compound within the pharmaceutical composition. The pharmaceutical composition comprises: (6{[4-(pyrazol-1-yl)benzyl](pyridine-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino)isopropyl acetate or a salt thereof; and polyoxyethylene castor oil. The polyoxyethylene castor oil preferably comprises a polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil. | 2020-04-16 |
20200113881 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY - Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof. | 2020-04-16 |
20200113882 | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions - Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy. | 2020-04-16 |
20200113883 | DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION - Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS. | 2020-04-16 |
20200113884 | METHOD OF PROVIDING PIRFENIDONE THERAPY TO A PATIENT - The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme. | 2020-04-16 |
20200113885 | Ferroportin-Inhibitor Salts - The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis. | 2020-04-16 |
20200113886 | COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT - Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release. | 2020-04-16 |
20200113887 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS - The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease. | 2020-04-16 |
20200113888 | USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY - The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP. | 2020-04-16 |
20200113889 | TRICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER - There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R | 2020-04-16 |
20200113890 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia. | 2020-04-16 |
20200113891 | NOVEL AMODIAQUINE ANALOGS AND METHODS OF USES THEREOF - Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat viral infections. | 2020-04-16 |
20200113892 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS - The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor. | 2020-04-16 |
20200113894 | Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments - This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. | 2020-04-16 |
20200113895 | Method of treating peripheral neuropathy - Compositions and methods for treating or preventing peripheral neuropathy in a subject determined to be in need thereof. The method comprises a step of topically administering to the subject anti-peripheral neuropathic compounds acting as GFR α 3 type receptor agonist. | 2020-04-16 |
20200113896 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer. | 2020-04-16 |
20200113897 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER - There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein W, X, Y, Z, R | 2020-04-16 |
20200113898 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES - Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody. | 2020-04-16 |
20200113899 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES - The present invention describes pharmaceutical combinations, compositions, and methods comprising a statin and 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine or a pharmaceutically acceptable salt and/or solvate thereof, that are useful for the treatment of synucleinopathic disorders. | 2020-04-16 |
20200113900 | BENZATHINE ANALOGS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 2020-04-16 |
20200113901 | METHODS OF USING EHMT2 INHIBITORS - The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes. | 2020-04-16 |
20200113902 | COMPOSITIONS AND METHODS FOR TREATING CANCERS WITH COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) - The present invention relates to methods of identifying subjects suffering from various types of cancer who are more likely to respond to treatment with a covalent CDK7 inhibitor, such as N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide (Compound 1), either alone or in combination with other classes of anti-cancer therapies based on the presence or absence of certain biomarkers. In addition, the present invention relates to combinations of Compound 1 and one or more other anti-cancer therapies, kits containing them, and the use of such combinations in treating subjects suffering from various types of cancers. | 2020-04-16 |
20200113903 | KINASE INHIBITOR SALTS, AND COMPOSITIONS THEREOF - The present invention relates to kinase inhibitor C | 2020-04-16 |
20200113904 | METHODS FOR TREATING HUNTINGTON'S DISEASE - The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. | 2020-04-16 |
20200113905 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS - Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1). | 2020-04-16 |
20200113906 | CROSSLINKED POLYMER NANOPARTICLES FOR TARGETED CELLULAR UPTAKE AND THERAPEUTICS, AND COMPOSITIONS AND METHODS THEREOF - The invention provides novel compounds, pharmaceutical compositions and methods of preparation and therapeutic use thereof. The invention also provides novel gel compositions comprising hyaluronic acid (HA) polymers that are crosslinked with appropriate reversible crosslinkers and encapsulation of therapeutics or other payloads in such gel composition and nanoparticles thereof. The invention also relates to targeted delivery of such gel compositions and nanoparticles to specific cell types in a controllable delivery and release. The invention additionally relates to methods of therapeutic use of such gel compositions and nanoparticles in treatment of various diseases and conditions. The invention further relates to methods of preparation of the gel compositions and nanoparticles disclosed herein. | 2020-04-16 |
20200113907 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES - A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. | 2020-04-16 |
20200113908 | COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H- -PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE - Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. | 2020-04-16 |
20200113909 | METHODS OF TREATING GLIOBLASTOMA - Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel. | 2020-04-16 |
20200113910 | TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES - The present invention relates to anew use of 4-phenoxy-phenyl-1,3,5-triazine derivatives or pharmaceutically acceptable salts thereof, according to formula I, wherein R | 2020-04-16 |
20200113911 | COMBINATION THERAPY FOR TREATING CANCER - The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. | 2020-04-16 |
20200113912 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates - Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates. | 2020-04-16 |
20200113913 | METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION - The present invention relates to compositions of Sonic Hedgehog (Shh) pathway activators and Wnt agonists and methods of using them to induce self-renewal of hair follicle stem cells, including inducing the hair follicle stem cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair follicle epithelial cells. | 2020-04-16 |
20200113914 | DEVICE AND METHOD OF USING VOLATILE ORGANIC COMPOUNDS THAT AFFECT MOOD, EMOTION OR A PHYSIOLOGICAL STATE - The present invention includes an apparatus and method for aiding mood, emotion, or physiological state comprising: a substrate that is capable of capturing or absorbing one or more organic compounds from a subject having a first physiologic or emotional state at a first time; and an element that is capable of controlling the capture of the one or more organic compounds at a first time, or the release of the one or more organic compounds from the substrate at a second time, wherein exposure to an effective amount of the organic compounds changes the mood, emotion, or physiological state of the subject. | 2020-04-16 |
20200113915 | METHODS AND DEVICES FOR CAPTURING VOLATILE ORGANIC COMPOUNDS - The present invention includes an apparatus and method for aiding mood, emotion, or physiological state comprising: a substrate that is capable of capturing or absorbing one or more organic compounds from a subject having a first physiologic or emotional state at a first time; and an element that is capable of controlling the capture of the one or more organic compounds at a first time, or the release of the one or more organic compounds from the substrate at a second time, wherein exposure to an effective amount of the organic compounds changes the mood, emotion, or physiological state of the subject. | 2020-04-16 |